Biopharma

Caris Life Sciences® is at the intersection of science, medicine and information – delivering invaluable solutions to biopharma companies and researchers developing the next generation of oncology precision medicines.

Icon_MI-Trial-Services

Clinical Trial Services

Designed to maximize the chances of success for clinical trials and address many patient accrual challenges facing biopharma partners in the world of precision medicine.

Icon_MI-Insights

MI Insights

Icon_Molecular-Testing

Molecular Testing Capabilities

Our data-driven, molecular insights are changing the landscape of precision medicine with actionable insights from retrospective, epidemiologic, and real-time molecular data to enhance research and commercial activities.

At our 66,000 square foot, state-of-the-art laboratory located in Phoenix, Arizona, we provide high quality, reliable molecular testing services for all stages of the drug development cycle and routine clinical use.

50+
Biopharma partnerships

Just-in-Time Research

J-I-T research is a rapid start-up/enrollment process where research sites screen for patients prior to activation. Using the J-I-T approach, Pharmatech can activate research sites on clinical trials within 10-14 days. The purpose of the program is to reduce the burden on research facilities, which allows them access to a larger number of potential trials when they have an eligible patient. This allows physicians at Pharmatech J-I-T sites to include clinical trials, not yet opened, in their treatment options for current and future patients.

Molecular Testing Capabilities

  • Next-Generation Sequencing (NGS): Caris has one of the most advanced sequencing laboratories in the world, which allows us to perform whole-exome DNA sequencing and whole transcriptome RNA sequencing on every patient.
    • DNA Sequencing: Caris Molecular Intelligence® DNA sequence analysis reliably detects DNA mutations, copy number variations, and gene fusions across the entire exome. Whole-exome DNA sequencing is performed on all tumor types and for every patient. As a consequence we are able to detect mutations, copy number variations, deletions in a large number of cancer-relevant genes and are able to determine presence of genome-wide loss of heterogeneity (LOH), microsatellite-instability (MSI), as well as tumor mutational burden (TMB) with exceptional precision.
    • RNA Sequencing: Whole transcriptome sequencing analysis is performed on every case and is the gold-standard method to detect clinically relevant aberrations, in particular gene-fusion events and splice variants. This is a result of the fact that RNA provides sequence information after gene splicing has happened thus avoiding the complexities of genomic features such as large intronic regions. Therefore, Caris Molecular Intelligence® has the ability to detect rare fusion events far better than DNA-based short-read methods, and provides broad coverage of all exons, capturing all possible fusion partners 
  • Immunohistochemistry (IHC): We evaluate protein biomarkers through an extensive immunohistochemical panel, which are applied in a tumor-type specific manner to conserve tissue and avoid unnecessary testing. Our large team of board-certified expert pathologists utilizes digital pathology and oversees application and interpretation of this technology.
  • In-situ Hybridization: For select genes, we offer ISH to provide higher level of resolution to our IHC results to detect amplification and fusion events.
  • Microdissection: Our Pathology team reviews every sample that is prepared for DNA and RNA sequence analysis and performs micro-dissection on every specimen, which results in a significant enrichment of the sample for DNA and RNA derived from the tumor. Because of this process, we are able to provide results in more than 95% of the cases and are able to detect molecular sub-clones present in the tumor.

Product Pipeline

We’re pushing the boundaries of precision medicine

Clinical Trials

Connecting patients with the most up-to-date and relevant clinical trials
Need Support?
Contact Us
or call 1.888.979.8669 (international: +41 21 533 53 00)